Heat Biologics, Inc.

Leading the Immuno-Oncology Revolution

Heat’s ImPACT Immunotherapy transforms living allogeneic human cancer cells into miniature osmotic pumps that continually secrete cancer antigens to activate a patient's own immune system to destroy the cancer cells.

Learn more about our science

About Us

Heat Biologics is a clinical-stage company focused on developing its proprietary “ImPACT” (Immune Pan-Antigen Cytotoxic Therapy) fully allogeneic “off-the-shelf” cell based immunotherapy to treat patients with a wide array of cancers and infectious diseases.

Learn more about Heat Biologics

View our corporate presentation

Recent News

Heat Biologics Announces Common Stock Rights Offering in Form S-1 Filing

Read More

Heat Biologics Granted Type C Meeting with FDA to Discuss Registrational Pathway for HS-110 in Combination with Opdivo(R) as a Treatment for Non-Small Cell Lung Cancer

Read More

Events

September 27, 2017

SeeThruEquity and RHK Capital 2017 Disruptive Growth Company Showcase NYC

October 5, 2017

The MicroCap Conference

ImPACT Therapy

A First-In-Class Fully Human Cytotoxic T Cell Specific Adjuvant

Heat Biologics’ proprietary ImPACT technology transforms allogenic living cells into miniature osmotic pumps that continually secrete heat shock protein gp96, the most potent mammalian adjuvant ever described, along with its chaperoned antigens.

View our product pipeline